Discontinuation
Stopping Tirzepatide
Stopping tirzepatide reverses its effects: appetite signalling returns to baseline and weight typically regains, as SURMOUNT-4 demonstrated in a randomised withdrawal design. There is no physical dependence and no withdrawal syndrome, but the metabolic effects end with the drug. Any decision to stop, and how, belongs with a prescriber.
Key takeaways
- Stopping reverses appetite suppression; SURMOUNT-4 showed substantial subsequent regain.
- There is no physical dependence or withdrawal syndrome.
- Regain is physiological, not a failure of willpower.
- Common reasons for stopping include cost, side effects, supply, and pregnancy planning.
- This site publishes no tapering or discontinuation schedules — those are prescriber decisions.
| Evidence | SURMOUNT-4 randomised withdrawal |
|---|---|
| Physical dependence | None described |
| Expected effect | Return of appetite signalling and weight regain |
| Common reasons | Cost, side effects, supply interruption, pregnancy planning |
| Tapering guidance | Not published here — prescriber decision |
What happens physically after the last dose?
Exposure declines over the following weeks given the roughly five-day half-life, and the appetite and gastric-emptying effects fade with it. Most people describe appetite returning rather than any withdrawal sensation, because the drug does not produce dependence.
SURMOUNT-4 quantified what follows: participants randomised to placebo after a successful lead-in regained substantially over 52 weeks, while those continuing held their loss.
Why is stopping so often framed as failure?
Because weight regain is culturally read as a personal lapse. The randomised evidence contradicts that: people who stopped regained even though nothing about their motivation changed at randomisation. The biology of appetite regulation reasserted itself, which is exactly what a drug that suppresses appetite while present would predict.
Framing regain as relapse discourages people from discussing discontinuation honestly with a prescriber, which is the opposite of useful.
What should happen before stopping?
A conversation with the prescriber about the reason. If cost is driving it, a different product, coverage pathway, or provider may address it. If side effects are driving it, a dose adjustment may. If pregnancy is planned, there are specific considerations. Stopping without that conversation forfeits options that may exist.
What the evidence shows
- Substantial weight regain following randomised withdrawal.
- Absence of physical dependence or a withdrawal syndrome.
What the evidence does not show
- That any tapering schedule prevents regain.
- That regain reflects behavioural failure.
Related: Weight regain · SURMOUNT-4
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does the evidence actually support about how to stop?
Very little, and that gap deserves stating plainly. SURMOUNT-4 established what happens after stopping — substantial regain — but it randomised participants to abrupt placebo substitution rather than comparing tapering strategies. No trial cited on this site establishes that any particular way of stopping produces a better outcome than another.
That is why this site publishes no tapering schedule. Not because the information is being withheld, but because the evidence to support a specific schedule does not exist, and inventing one would be presenting a guess as guidance.
What is worth doing before stopping rather than after?
Understanding why. If cost is driving the decision, an insurance appeal, a manufacturer programme, or a different pathway may address it, and those take time to arrange. If side effects are driving it, a dose reduction may resolve the problem while preserving benefit. If pregnancy is planned, there are specific timing considerations.
Stopping without that conversation forfeits options that may exist, and restarting later is not always straightforward — supply, coverage, and re-escalation all re-enter the picture.
What does this page cover, and what does it deliberately leave out?
This page addresses Supervision, withdrawal evidence, appetite and regain and access, organised around the primary question of stopping tirzepatide. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Supervision | Covered on this page | Primary evidence |
| Withdrawal evidence | Covered on this page | Primary evidence |
| Appetite | Covered on this page | Primary evidence |
| Regain and access | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on stopping tirzepatide.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 4 technical terms this page uses, including DOI, half-life, placebo, randomised withdrawal — in the specific sense used above.
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
|---|---|
| half-life | The time taken for the amount of drug in the body to fall by half. Tirzepatide's is roughly five days, which supports once-weekly dosing and means steady state takes several weeks. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| randomised withdrawal | A design in which everyone first receives the active drug, and only those who respond are then randomised to continue or stop. SURMOUNT-4 used this design, which is why its regain finding cannot be explained away by differences between groups. |
Frequently asked questions
What happens when you stop taking tirzepatide?
Appetite signalling returns to baseline and weight typically regains, as shown in SURMOUNT-4.
Is there a withdrawal syndrome?
No physical dependence or withdrawal syndrome is described.
Should I taper off?
That is a prescriber decision. This site does not publish tapering schedules.
Can I restart later?
Restarting is a clinical decision; discuss it with your prescriber rather than self-managing.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.